Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.50 |
| ▸ | CNR1 | P21554 | 3/20 | 0.48 |
| ▸ | TACR2 | P21452 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | CTSA | P10619 | 8/20 | 0.44 |
| ▸ | KMO | O15229 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411082 | 0.90 | CNR1 (0.49) | KDM4CCNR1TACR2ABL1CTSA | |
| SCHEMBL411999 | 0.90 | CTSA (0.50) | KDM4CCNR1TACR2ABL1CTSA | |
| SCHEMBL2703056 | 0.85 | CNR1 (0.63) | CNR1TACR2ABL1CTSACNR2 | |
| SCHEMBL411066 | 0.83 | CNR1 (0.48) | KDM4CCNR1CTSAKMO | |
| SCHEMBL14908756 | 0.78 | HCAR3 (0.43) | CNR1TACR2ABL1CTSARARG | |
| SCHEMBL410672 | 0.77 | ABL1 (0.43) | CNR1TACR2ABL1CTSACNR2 | |
| SCHEMBL412339 | 0.77 | CNR1 (0.52) | CNR1KMOCNR2 | |
| SCHEMBL14761470 | 0.76 | CNR1 (0.48) | CNR1ABL1CTSACNR2 | |
| SCHEMBL412159 | 0.76 | CNR1 (0.48) | CNR1CTSACNR2 | |
| SCHEMBL411087 | 0.74 | CNR1 (0.51) | CNR1TACR2CTSACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2613785-A1 | HETEROARYLMETHYL AMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| CN-103118680-A | Heteroarylmethyl amides | HOFFMANN LA ROCHE | 2013-05-22 | — | — | CN | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | KDM4C 1964/4885CNR1 269/4885TACR2 1840/4885 |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | KDM4C 1964/4885CNR1 269/4885TACR2 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.